Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

No longer available 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 1Expanded_access 1

Sponsor

Cancer Type

Tumor-Agnostic 3Genitourinary 3Thoracic 2Sarcoma 2Lymphoid 2CNS 2Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Breast 1

Conditions

Lung Neoplasms 2Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 1174Cisplatin 891Pemetrexed 847pembrolizumab 626Paclitaxel 609Docetaxel 539Gemcitabine 428Radiotherapy 393Erlotinib Hydrochloride 381Nivolumab 344Bevacizumab 337Etoposide 297durvalumab 264Drug Therapy 260osimertinib 237atezolizumab 225Radiosurgery 196Gefitinib 186Vinorelbine 149Magnetic Resonance Spectroscopy 132Ipilimumab 129130-nm albumin-bound paclitaxel 125Cetuximab 113Blood Specimen Collection 106anlotinib 105tislelizumab 103Topotecan 103Specimen Handling 102Surgical Procedures, Operative 101Cyclophosphamide 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Suspensions × Thoracic × Clear all
NCT03756311 2026-01-23

Expanded Access to NanoPac

NanOlogy, LLC

No longer available
GenitourinaryThoracic

Lung Neoplasms, Prostatic Neoplasms

NCT04314895 2025-05-23

Trial of NanoPac Intratumoral Injection in Lung Cancer

NanOlogy, LLC

Phase 2 Completed
18 enrolled 12 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡